Wall Street analysts expect Esperion Therapeutics Inc (NASDAQ:ESPR) to report sales of $930,000.00 for the current quarter, Zacks reports. Three analysts have provided estimates for Esperion Therapeutics’ earnings, with the lowest sales estimate coming in at $900,000.00 and the highest estimate coming in at $1.00 million. The company is expected to report its next quarterly earnings report before the market opens on Thursday, August 8th.
On average, analysts expect that Esperion Therapeutics will report full-year sales of $148.13 million for the current year, with estimates ranging from $145.42 million to $150.00 million. For the next financial year, analysts expect that the business will post sales of $160.36 million, with estimates ranging from $7.10 million to $207.50 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Esperion Therapeutics.
Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported $3.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $2.43. The firm had revenue of $145.42 million for the quarter, compared to analyst estimates of $69.35 million. During the same period last year, the company earned ($1.73) EPS.
NASDAQ:ESPR traded down $0.52 during mid-day trading on Friday, hitting $39.17. The company had a trading volume of 6,051 shares, compared to its average volume of 369,661. Esperion Therapeutics has a fifty-two week low of $36.06 and a fifty-two week high of $60.99. The company has a fifty day moving average price of $46.31. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of -5.25 and a beta of 1.72.
In other news, CEO Timothy M. Mayleben acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, June 28th. The stock was acquired at an average cost of $46.00 per share, for a total transaction of $230,000.00. Following the completion of the acquisition, the chief executive officer now owns 66,163 shares in the company, valued at $3,043,498. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Target N. V. Biotech acquired 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were purchased at an average price of $42.65 per share, with a total value of $2,132,500.00. Following the completion of the acquisition, the insider now owns 3,572,964 shares of the company’s stock, valued at approximately $152,386,914.60. The disclosure for this purchase can be found here. Company insiders own 7.70% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Aperio Group LLC bought a new position in shares of Esperion Therapeutics during the second quarter worth about $29,000. Advisor Group Inc. grew its holdings in shares of Esperion Therapeutics by 44.4% during the fourth quarter. Advisor Group Inc. now owns 947 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 291 shares in the last quarter. Parallel Advisors LLC bought a new position in shares of Esperion Therapeutics during the first quarter worth about $80,000. Steward Partners Investment Advisory LLC bought a new position in shares of Esperion Therapeutics during the second quarter worth about $165,000. Finally, Marshall Wace North America L.P. bought a new position in Esperion Therapeutics in the first quarter valued at approximately $164,000.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Recommended Story: Book Value Per Share – BVPS
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.